More than 2,000 known CFTR mutations have been identified worldwide. The type of mutation a patient carries can alter everything from how severe their symptoms are to what drugs will work for them.
A study led by researchers at UT Southwestern, published in the Journal of Clinical Investigation, suggests that a protein secreted by immune cells within these tumors causes them to grow even in the absence of estrogen.
Researchers at Washington University School of Medicine in St. Louis have developed a new tool to detect reconstruction-related infections early, before they cause symptoms.
Researchers from the Institute of Industrial Science, The University of Tokyo have used 3D-printing technology to improve the viral titer of microneedle array patches, resulting in effective immunogenicity and protection against infection in mice.
A research team led by Professor Víctor Yuste, from the Department of Biochemistry and Molecular Biology and the Institut de Neurociències de la UAB (INc-UAB), has designed and tested several bioadhesive patches that could be placed at the site where the tumor is removed during surgery, targeting any remaining cancer cells.
Insulet (Nasdaq:PODD) announced today that it launched its Omnipod 5 and Omnipod Discover offerings in the Middle East.
Based on a virus-like particle built with a DNA scaffold, the approach could generate broadly neutralizing antibody responses against HIV or influenza.
With this FDA approval, Hologic now offers three guideline-recommended methods: Pap testing, HPV primary testing, and co-testing.
A new type of brain implant may have implications for both brain research and future treatments of neurological diseases such as epilepsy.
An experimental pill called enlicitide slashed levels of low-density lipoprotein (LDL) cholesterol, commonly known as “bad” cholesterol, by up to 60%, according to a new phase three clinical trial published in the New England Journal of Medicine.